GlassScriptPhysician profile
Khaled Shafiei
NPI 1922034487
$3,758.35
in general payments reported to CMS, 2019-2025
43 companies · $714 in 2025
The $714 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $499 · 2021: $315 · 2022: $428 · 2023: $699 · 2024: $414 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,820 · Education: $6.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,820.00 |
| Education | $6.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $446.14 | 2019-2025 | Nuplazid |
| Bayer Healthcare Pharmaceuticals INC. | $358.89 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $267.25 | 2022-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Avanir Pharmaceuticals, INC. | $256.34 | 2019-2022 | |
| Abbvie INC. | $222.01 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $192.15 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $180.19 | 2019-2023 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $168.23 | 2019-2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.16 | 2019-2025 | Jardiance, Tradjenta |
| Corcept Therapeutics | $121.54 | 2024-2025 | Korlym |
| Lundbeck LLC | $113.46 | 2023-2025 | Rexulti |
| Pfizer INC. | $109.70 | 2019-2023 | |
| Lilly USA, LLC | $84.06 | 2019-2025 | Mounjaro, Jardiance |
| Paratek Pharmaceuticals, INC. | $82.10 | 2019-2024 | Nuzyra |
| Allergan, INC. | $82.05 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Shafiei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.